Our focus at Fos Biomedical is in the research and development of photobiomodulation products to improve peoples health. We have a growing portfolio of products that incorporate this technology into a convenient non-transdermal patch.
We are invested in the research of our products and new product developments to provide proven PBM products in this innovative area.
A RANDOMIZED, PLACEBO-CONTROLLED, CROSSOVER TRIAL
Effects of the Fos Biomedical devices on Cardio-metabolic Risk Factors and Sleep Quality in Adults at Risk for Type 2 Diabetes: A Randomized, Placebo-controlled, Crossover Trial at the Yale-Griffin Prevention Center.
The effects of the non-transdermal Fos Biomedical devices (which utilizes the concept of photobiomodulation) on cardio-metabolic risk factors and sleep quality in people at risk for type 2 diabetes are unclear. Proposed is a randomized crossover placebo-controlled trial to assess the impact of the Fos Biomedical devices use on cardio-metabolic risk factors and sleep quality, among adults at risk for type 2 diabetes.
Viral Response Pilot Study
The pilot study explored the impact of wearing two Fos Biomedical devices in combination with orally administered Copper Glycinate (2mg BID). It is believed that the combination of this particular form of light therapy in conjunction with copper ions will produce an antiviral effect.
We are developing a portfolio of PBM patch products in the areas of pain management, viral infection and blood sugar management.
All devices are non-invasive and are intended for modifying the biological or chemical composition of human tissues or cells, blood, other body liquids or other liquids intended for implantation or administration.